Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 24;10.1111/bph.15072.
doi: 10.1111/bph.15072. Online ahead of print.

Current Pharmacological Treatments for COVID-19: What's Next?

Free PMC article

Current Pharmacological Treatments for COVID-19: What's Next?

Cristina Scavone et al. Br J Pharmacol. .
Free PMC article


Since December 2019 SARS-Cov-2 was found responsible for the disease COVID-19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID-19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVID-19, focusing on their antiviral, immune-modulatory and/or anti-inflammatory actions. Where available, data from clinical trials involving patients with COVID-19 are reported. Preliminary clinical trials seem to support their benefit. However, such drugs in COVID-19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. Nevertheless, while waiting for effective preventive measures i.e. vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. Their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications.

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles


    1. Adnkronos . (2020). Coronavirus, antivirale remdesivir sperimentato in 12 centri Italiani. Available at: (March 2020).
    1. Agenzia Italiana del Farmaco a . (2020). Aggiornamento sui farmaci resi disponibili per COVID‐19 al di fuori delle indicazioni terapeutiche Available at: (March 24th 2020).
    1. Agenzia Italiana del Farmaco b . (2020). Favipiravir: aggiornamento della valutazione della CTS. Available at: (March 23th 2020).
    1. Agenzia Italiana del Farmaco c . (2020). Comunicazione AIFA sull'utilizzo di Clorochina e Idrossiclorochina nella terapia dei pazienti affetti da COVID‐19 ‐ Informazioni di sicurezza. Available at: (March 31st 2020).
    1. Agenzia Italiana del Farmaco d . (2019). RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO. Available at: about:blank

LinkOut - more resources